David Allison, PhD
Dr. Allison has spent the past 15 years in biotechnology venture capital and has led several IPOs and acquisitions. Before joining Westlake, he spent more than six years as a partner at 5AM Ventures where he was involved in investments including CinCor Pharma (acquired by AstraZeneca), Crinetics Pharmaceuticals, Impel Neuropharma, Inipharm, Neurogastrx, and Radionetics. Prior to 5AM, Dr. Allison was a principal at Versant Ventures and held previous roles at Split Rock Partners and PTV Healthcare Capital.